Screener
Enliven Therapeutics ELVN Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none | — | — |
| Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 60,889,655 and 59,440,045 atMarch 31, 2026 and December 31, 2025, respectively | 61 | 59 |
| Additional paid-in capital | 824,479 | 806,373 |
| Accumulated other comprehensive (loss) income | (382) | 334 |
| Accumulated deficit | (370,793) | (347,166) |
| Total stockholders’ equity | 453,365 | 459,600 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's common stock?
- Enliven Therapeutics (ELVN) reported common stock of $61K in Q1 2026.
- How has Enliven Therapeutics's common stock changed year-over-year?
- Enliven Therapeutics's common stock increased by 24.5% year-over-year, from $49K to $61K.
- What is the long-term trend for Enliven Therapeutics's common stock?
- Over 5 years (2020 to 2025), Enliven Therapeutics's common stock has grown at a 26.8% compound annual growth rate (CAGR), from $18K to $59K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Enliven Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude